Verrica Pharmaceuticals Inc (NASDAQ:VRCA) Short Interest Update

Share on StockTwits

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) was the target of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totalling 573,300 shares, a decrease of 10.7% from the December 15th total of 641,900 shares. Approximately 4.7% of the company’s shares are short sold. Based on an average daily volume of 74,100 shares, the days-to-cover ratio is currently 7.7 days.

NASDAQ VRCA traded up $0.27 during trading hours on Thursday, hitting $15.77. 1,848 shares of the company traded hands, compared to its average volume of 61,593. The business’s 50-day moving average is $15.00 and its 200-day moving average is $13.08. Verrica Pharmaceuticals has a twelve month low of $6.84 and a twelve month high of $18.67. The stock has a market capitalization of $403.38 million, a price-to-earnings ratio of -11.21 and a beta of 4.10.

Verrica Pharmaceuticals (NASDAQ:VRCA) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.03. As a group, research analysts forecast that Verrica Pharmaceuticals will post -1.13 EPS for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the business. State Street Corp raised its stake in Verrica Pharmaceuticals by 14.9% in the third quarter. State Street Corp now owns 208,426 shares of the company’s stock valued at $3,076,000 after buying an additional 27,098 shares during the period. Rhumbline Advisers raised its stake in Verrica Pharmaceuticals by 5.6% in the third quarter. Rhumbline Advisers now owns 16,918 shares of the company’s stock valued at $250,000 after buying an additional 898 shares during the period. Bank of America Corp DE raised its stake in Verrica Pharmaceuticals by 18.8% in the second quarter. Bank of America Corp DE now owns 101,242 shares of the company’s stock valued at $1,176,000 after buying an additional 16,009 shares during the period. Vanguard Group Inc. raised its stake in Verrica Pharmaceuticals by 6.0% in the second quarter. Vanguard Group Inc. now owns 457,103 shares of the company’s stock valued at $5,312,000 after buying an additional 25,858 shares during the period. Finally, BlackRock Inc. raised its stake in Verrica Pharmaceuticals by 31.1% in the second quarter. BlackRock Inc. now owns 634,441 shares of the company’s stock valued at $7,374,000 after buying an additional 150,679 shares during the period. Hedge funds and other institutional investors own 35.96% of the company’s stock.

A number of research firms have issued reports on VRCA. Zacks Investment Research cut Verrica Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. ValuEngine raised Verrica Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, January 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $24.00 target price on shares of Verrica Pharmaceuticals in a research note on Wednesday, November 27th.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts.

Read More: What are the benefits of a balanced fund?

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.